MDXG

Mimedx Group Stock Analysis

AI Rating

Fair
  • Quality9/10
  • Growth↓ 0/10
  • Momentum↓ 2/10
Mimedx Group sales and earnings growth
MDXG Growth
Low
  • Revenue Y/Y↑ 14.77%
  • EPS Y/Y↓ -55.56%
  • FCF Y/Y↑ 19.69%
Mimedx Group gross and profit margin trends
MDXG Profitability
Great
  • Gross margin ↑ 82.00%
  • EPS margin↑ 10.40%
  • ROIC↑ 49.90%
Mimedx Group net debt vs free cash flow
MDXG Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 21.9

Mimedx Group stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗